Review article:: systemic and topical steroids in inflammatory bowel disease

被引:19
|
作者
Schölmerich, J [1 ]
机构
[1] Klinikum Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany
关键词
D O I
10.1111/j.1365-2036.2004.02059.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Steroids are still widely used in the treatment of inflammatory bowel diseases. Pharmacological studies have shown that there is no major abnormality in the pharmacokinetics of steroids in these disorders. Foam preparations with rectal application decrease the bioavailability to low levels, eliminating systemic complications. For oral use, 'nonsystemic' steroids have been developed. In ulcerative colitis. steroids are rarely needed as 5-aminosalicylates are effective in the majority of patients. This is true for rectal application in distal colitis, as well as in more extensive disease. In Crohn's disease, steroids are more often used; however, in population-based studies, less than 50% of patients have been treated with steroids, as there are alternative treatments available for the large group of patients with mild to moderate activity. For those patients needing steroid treatment, budesonide seems to be a good choice in active disease, but has not shown convincing effects in the maintenance of remission over longer periods of time. There is no place for long-term steroid treatment in ulcerative colitis and very little in Crohn's disease - immunosuppression with azathioprine or related drugs is certainly the better alternative.
引用
收藏
页码:66 / 74
页数:9
相关论文
共 50 条
  • [31] Review article: complementary and alternative therapies for inflammatory bowel disease
    Langmead, L
    Rampton, DS
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (03) : 341 - 349
  • [32] Review article: diet and inflammatory bowel disease - epidemiology and treatment
    Yamamoto, T.
    Nakahigashi, M.
    Saniabadi, A. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (02) : 99 - 112
  • [33] Review article: skin complications associated with inflammatory bowel disease
    Veloso, FT
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 50 - 53
  • [34] Review article: biological activity markers in inflammatory bowel disease
    Desai, D.
    Faubion, W. A.
    Sandborn, W. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (03) : 247 - 255
  • [35] Review article: the role of nutrition in the treatment of inflammatory bowel disease
    Gassull, MA
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 79 - 83
  • [36] Review article: helminths as therapeutic agents for inflammatory bowel disease
    Hunter, MM
    Mckay, DM
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (02) : 167 - 177
  • [37] Topical Therapies in Inflammatory Bowel Disease
    Frei, Pascal
    Biedermann, Luc
    Manser, Christine N.
    Wilk, Maike
    Manz, Michael
    Vavricka, Stephan R.
    Rogler, Gerhard
    DIGESTION, 2012, 86 : 36 - 44
  • [38] The Role of Topical Tacrolimus in the Management of Inflammatory Bowel Disease: A Comprehensive Review
    Khayatan, Danial
    Lemberg, Daniel A.
    Day, Andrew S.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (18)
  • [39] Use of Systemic Steroids in the Management of Inflammatory Bowel Disease and Its Effects on Intraocular Pressure
    Gill, Amrik
    Wong, Uni
    Noyes, Abigail R.
    Swamy, Ramya
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S321 - S322
  • [40] Review article: inflammatory bowel disease - empowering the patient and improving outcome
    Robinson, A
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 84 - 87